Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2010 May;87(5):553-7. doi: 10.1038/clpt.2010.3. Epub 2010 Mar 24.

Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.

Author information

  • 1Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA. clerman@mail.med.upenn.edu

Abstract

In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers (RMs) of nicotine but not in normal metabolizers (NMs). RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism.

PMID:
20336063
[PubMed - indexed for MEDLINE]
PMCID:
PMC3896974
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk